PCM
ALNY icon

Prelude Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prelude Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,800
Closed -$1.5M – 1336
2017
Q3 		$1.5M Buy
+12,800
New +$1.09M 0.14% 157
2015
Q3 		– Sell
-3,800
Closed -$456K – 1456
2015
Q2 		$456K Hold
3,800
– – 0.06% 334
2015
Q1 		$397K Buy
+3,800
New +$385K 0.06% 409

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's ALNY Position: Q1 2026 in Review

Prelude Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 928 shares — an estimated $369K sold.

Prelude Capital Management first reported a position in ALNY in Q2 2013 and held it in 22 quarters. The position peaked at $2M in Q1 2021. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Prelude Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 928 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Prelude Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Prelude Capital Management's Alnylam Pharmaceuticals position peaked at $2M in Q1 2021.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.